THIS WARRANT AND THE SHARES ISSUABLE UPON THE EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. EXCEPT AS OTHERWISE SET FORTH HEREIN NEITHER THIS WARRANT NOR ANY OF SUCH SHARES MAY BE SOLD, TRANSFERRED OR...DanDrit Biotech USA, Inc. • February 9th, 2018 • Pharmaceutical preparations • Delaware
THIS Common Stock Purchase Warrant CERTIFIES THAT, for value received, ____________ or his registered assigns (“Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 PM Eastern Standard Time on December 31, 2019 (the “Expiration Date”) but not thereafter, to subscribe for and purchase from DanDrit Biotech USA, Inc., a Delaware corporation with offices at Stumpedyssevej 17, 2970 Hørsholm, Denmark (the “Company”) an aggregate of up to 300,000 shares of common stock, par value $0.0001 per share, of the Company (the “Shares”), at an initial price per Share of $2.00, as adjusted in accordance with Section 2 below (the “Purchase Price”).
AMENDMENT NO. 1 TO CONVERTIBLE PROMISSORY NOTEConvertible Promissory Note • February 9th, 2018 • DanDrit Biotech USA, Inc. • Pharmaceutical preparations
This Amendment No. 1 to Convertible Promissory Note (this “Amendment”), dated as of _________, 2017 (the “Effective Date”), is entered into by and between DanDrit Biotech USA, Inc., a Delaware corporation (the “Company”), and ___________ (the “Holder”).
CONSULTING AGREEMENTConsulting Agreement • February 9th, 2018 • DanDrit Biotech USA, Inc. • Pharmaceutical preparations • Delaware
This Consulting Agreement (this “Agreement”) is entered into as of December 29, 2017 (the “Effective Date”), by and between DanDrit Biotech USA, Inc., a Delaware corporation (the “Company”) and RS Group ApS, a Danish limited company, organized under the Danish Act on Limited Companies of the Kingdom of Denmark (“RS Group”).
AMENDMENT NO. 1 TO CFO SERVICE AGREEMENTCfo Service Agreement • February 9th, 2018 • DanDrit Biotech USA, Inc. • Pharmaceutical preparations
THIS AMENDMENT NO. 1 (this “Amendment”) to the CFO Service Agreement dated June 30, 2017 (the “Agreement”) is entered into as of December 29, 2017 (the “Effective Date”), by and among DANDRIT BIOTECH BIOTECH A/S., CVR no. 26 02 73 22, a Denmark corporation (the “Company”) and the Crossfield, Inc., Robert E. Wolfe (the “Consultant” and together with the Company, the “Parties”). Capitalized terms not Defined herein shall have the meaning set forth in the Agreement.
